Zydus Lifesciences Limited (ZYDUSLIFE.BO)
INR 859.55
(2.64%)
INR 859.55
(2.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 3.91 Billion INR | -44.68% |
| 2023 | 7.07 Billion INR | -80.15% |
| 2022 | 35.63 Billion INR | -9.62% |
| 2021 | 39.42 Billion INR | -45.0% |
| 2020 | 71.68 Billion INR | -4.15% |
| 2019 | 74.78 Billion INR | 53.57% |
| 2018 | 48.7 Billion INR | 32.93% |
| 2017 | 36.63 Billion INR | 103.17% |
| 2016 | 18.03 Billion INR | -10.98% |
| 2015 | 20.25 Billion INR | -5.85% |
| 2014 | 21.51 Billion INR | -7.81% |
| 2013 | 23.34 Billion INR | 28.05% |
| 2012 | 18.22 Billion INR | 150.54% |
| 2011 | 7.27 Billion INR | -13.64% |
| 2010 | 8.42 Billion INR | -17.05% |
| 2009 | 10.15 Billion INR | 36.3% |
| 2008 | 7.45 Billion INR | 110.18% |
| 2007 | 3.54 Billion INR | -11.24% |
| 2006 | 3.99 Billion INR | 23.96% |
| 2005 | 3.22 Billion INR | -18.1% |
| 2004 | 3.93 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 3.91 Billion INR | -44.68% |
| 2024 Q1 | - INR | -100.0% |
| 2024 Q4 | 3.91 Billion INR | 0.0% |
| 2024 Q3 | - INR | 100.0% |
| 2024 Q2 | -1.54 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 7.07 Billion INR | -80.15% |
| 2023 Q4 | 7.07 Billion INR | 0.0% |
| 2023 Q2 | 19.91 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 35.63 Billion INR | 0.0% |
| 2022 FY | 35.63 Billion INR | -9.62% |
| 2022 Q2 | 43.04 Billion INR | 0.0% |
| 2021 Q2 | 50.93 Billion INR | 0.0% |
| 2021 Q4 | 39.42 Billion INR | 0.0% |
| 2021 FY | 39.42 Billion INR | -45.0% |
| 2020 Q4 | 71.68 Billion INR | 0.0% |
| 2020 FY | 71.68 Billion INR | -4.15% |
| 2020 Q2 | 66.45 Billion INR | 0.0% |
| 2019 Q2 | 49.09 Billion INR | 0.0% |
| 2019 FY | 74.78 Billion INR | 53.57% |
| 2019 Q4 | 74.78 Billion INR | 0.0% |
| 2018 Q2 | 44.09 Billion INR | 0.0% |
| 2018 Q4 | 48.7 Billion INR | 0.0% |
| 2018 FY | 48.7 Billion INR | 32.93% |
| 2017 Q2 | 16.84 Billion INR | 0.0% |
| 2017 FY | 36.63 Billion INR | 103.17% |
| 2017 Q4 | 36.63 Billion INR | 0.0% |
| 2016 Q4 | 18.03 Billion INR | 0.0% |
| 2016 FY | 18.03 Billion INR | -10.98% |
| 2016 Q2 | 10.08 Billion INR | 0.0% |
| 2015 Q2 | 17.8 Billion INR | 0.0% |
| 2015 Q4 | 20.25 Billion INR | 0.0% |
| 2015 FY | 20.25 Billion INR | -5.85% |
| 2014 Q4 | 21.51 Billion INR | 0.0% |
| 2014 Q2 | 24.01 Billion INR | 0.0% |
| 2014 FY | 21.51 Billion INR | -7.81% |
| 2013 FY | 23.34 Billion INR | 28.05% |
| 2013 Q2 | 17.02 Billion INR | 0.0% |
| 2013 Q4 | 23.34 Billion INR | 0.0% |
| 2012 Q4 | 18.22 Billion INR | 0.0% |
| 2012 FY | 18.22 Billion INR | 150.54% |
| 2011 FY | 7.27 Billion INR | -13.64% |
| 2010 FY | 8.42 Billion INR | -17.05% |
| 2009 FY | 10.15 Billion INR | 36.3% |
| 2008 FY | 7.45 Billion INR | 110.18% |
| 2007 FY | 3.54 Billion INR | -11.24% |
| 2006 FY | 3.99 Billion INR | 23.96% |
| 2005 FY | 3.22 Billion INR | -18.1% |
| 2004 FY | 3.93 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -1.192% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -5.922% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 237.618% |
| Granules India Limited | 9.28 Billion INR | 57.876% |
| Indoco Remedies Limited | 6.47 Billion INR | 39.595% |
| Achyut Healthcare Limited | -3.74 Million INR | 104531.393% |
| Ajanta Pharma Limited | -954.9 Million INR | 509.676% |
| Alkem Laboratories Limited | -1.6 Billion INR | 343.072% |
| Alpa Laboratories Limited | 35.36 Million INR | -10962.41% |
| Brooks Laboratories Limited | 49.48 Million INR | -7805.426% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 178.046% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -18.583% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 437.896% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 69.705% |
| Eris Lifesciences Limited | 13.8 Billion INR | 71.665% |
| FDC Limited | -57.75 Million INR | 6873.791% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 191.29% |
| Gufic Biosciences Limited | 3.19 Billion INR | -22.467% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 194.196% |
| Ipca Laboratories Limited | 11.41 Billion INR | 65.73% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 381.453% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -102.388% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1800.884% |
| Laurus Labs Limited | 24.38 Billion INR | 83.957% |
| Lupin Limited | 17.19 Billion INR | 77.246% |
| Mankind Pharma Limited | -9.9 Billion INR | 139.483% |
| Medicamen Biotech Limited | 160.31 Million INR | -2340.181% |
| Medico Remedies Limited | 78.67 Million INR | -4872.228% |
| Megasoft Limited | 1.28 Billion INR | -204.305% |
| NATCO Pharma Limited | -5.81 Billion INR | 167.251% |
| Piramal Pharma Limited | 42.27 Billion INR | 90.747% |
| RPG Life Sciences Limited | -364.7 Million INR | 1172.662% |
| Sigachi Industries Limited | 859.94 Million INR | -354.911% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 105.398% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2598.378% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -8365.517% |
| Unichem Laboratories Limited | 931.91 Million INR | -319.78% |
| Wanbury Limited | 1.1 Billion INR | -253.747% |
| Windlas Biotech Limited | -273.04 Million INR | 1532.757% |
| ZIM Laboratories Limited | 983.6 Million INR | -297.721% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 515.375% |
| Divi's Laboratories Limited | -39.77 Billion INR | 109.837% |
| Hester Biosciences Limited | 2.29 Billion INR | -70.775% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 266.61% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1672.398% |
| Bal Pharma Limited | 1.26 Billion INR | -209.601% |
| Strides Pharma Science Limited | 23.25 Billion INR | 83.179% |
| Venus Remedies Limited | -267.7 Million INR | 1561.337% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -49.776% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 36.466% |
| Shilpa Medicare Limited | 9.06 Billion INR | 56.867% |
| Aarti Drugs Limited | 5.54 Billion INR | 29.493% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 455.217% |
| Suven Life Sciences Limited | -1.63 Billion INR | 339.603% |
| Ind-Swift Limited | 9.5 Billion INR | 58.858% |
| Valiant Laboratories Limited | -295.03 Million INR | 1425.958% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -38.664% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 60.993% |
| Themis Medicare Limited | 764.96 Million INR | -411.398% |
| Hikal Limited | 7.96 Billion INR | 50.897% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 87.71% |
| Sequent Scientific Limited | 4.17 Billion INR | 6.381% |
| Novartis India Limited | -5.89 Billion INR | 166.405% |
| Wockhardt Limited | 18.27 Billion INR | 78.588% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 85.55% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 21307.85% |
| Neuland Laboratories Limited | -214.05 Million INR | 1927.542% |
| Morepen Laboratories Limited | -231.17 Million INR | 1792.232% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -3158.941% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -300.897% |